In an initial study, we compared quantitative transcriptome data across mouse brain territories using the serial analysis of gene expression method. Among the novel regional markers that we discovered, we focused on a striatum-enriched transcript with no available experimental cDNA sequence. Here, we report its cloning, gene structure, and detailed distribution in mouse brain. Quantitative RT-PCR and in situ hybridization demonstrated predominant expression in dorsolateral striatum. We therefore named it capucin for caudate-and putamen-enriched sequence. Mouse capucin is a 237-amino-acid protein, without any registered ortholog in mammalian species. It contains no recognizable motif other than two predicted carboxy-terminal transmembrane domains. When expressed in fusion with a fluorescent protein, it localized to the Golgi apparatus in two mammalian cell lines. Interestingly, we observed a significant down-regulation of capucin mRNA levels in two rodent models of Huntington disease, indicating a possible contribution to the pathogenesis of this disorder. D
To perform highly integrated tasks, the mammalian brain relies on a complex network architecture involving specialized anatomical structures. Assuming that functional specificity is determined by the expression of unique sets of genes, transcriptome analysis of brain regions could provide valuable information on their physiology. The striatum, a basal ganglion participating in the control of movement, is particularly suited to such global-scale approaches. First, it is specifically involved in several neurodegenerative conditions. Severe atrophy of the striatum, due to the selective loss of medium spiny neurons, is a characteristic feature of Huntington disease [1] . In Parkinson disease, the degeneration of nigral dopaminergic neurons results in dopamine depletion in the striatum [2] . Furthermore, a number of psychoactive drugs target striatal dopaminergic synapses. For instance, cocaine and amphetamine increase dopaminergic activity through the impairment of dopamine transporter function [3 -5] , while most antipsychotics reduce the efficiency of dopamine neurotransmission by blocking D2 receptors [6] . Second, the cell composition of the striatum is not as complex as that of many other brain regions [2] . Finally, the striatum is easily accessible to experimentation. Even in small animals such as mice, it appears as a massive structure with distinctive anatomical features and well-defined boundaries [7] .
Most global analyses of gene expression in the striatum have been carried out in animal models of Huntington disease [8] , Parkinson disease [9, 10] , and addiction [11] . Studies designed to find constitutive striatal markers are sparser. In an early publication, nine independent cDNAs were cloned from a rat striatum library from which cerebellar cDNAs had been subtracted. Subsequent investigation of other brain regions demonstrated the enrichment of the corresponding transcripts in the striatum [12] . Among them, one was further characterized as Rasd2 (originally named Rhes), a Ras-related small GTP-binding protein up-regulated by thyroid hormone during postnatal brain maturation [13 -15] . More recently, differential display of RNA from seven rat brain regions led to the isolation of Gpr88, a striatum-specific orphan G-protein-coupled receptor whose sequence and expression pattern are conserved in human and mouse [16] .
To discover novel constitutive markers of the striatum, we have generated quantitative expression data on a global scale for various mouse brain territories [17] . For this purpose, we used the serial analysis of gene expression (SAGE) method, which offers the opportunity to detect new or poorly characterized transcripts [18] . We then compared SAGE data between the striatum and other brain regions and drew up a list of striatum-enriched transcripts, a number of which had never been described before [17] . In the present paper, we report the cDNA cloning and gene structure of one of these novel markers and provide a detailed analysis of its expression pattern in wild-type mouse brain. It was originally termed striatal marker 20 (StM20), but will be henceforth referred to as capucin for caudate-and putamen-enriched sequence. As a first step toward the characterization of the corresponding protein, we present results from homology searches and heterologous expression experiments. Finally, to investigate the possible role of capucin in striatal pathophysiology, we measured its mRNA levels in two rodent models of Huntington disease.
Results

cDNA cloning and gene structure of capucin
We initially identified capucin as a striatum-enriched mRNA species (StM20) in a SAGE analysis of wild-type mouse brain regions [17] . The principle of this method is to sequence one 10-bp-long tag from each molecule of an oligo(dT)-primed cDNA library [18] . The main SAGE tag (tag 1) corresponding to capucin matches UniGene cluster Mm.152484. We therefore designed an antisense oligonucleotide probe in the vicinity of tag 1 within this cluster ( Fig. 1) and hybridized it to a mouse poly(A) + RNA Northern blot. Two transcripts of approximately 2.7 and 2.8 kb, with comparable abundance, were detected in the whole brain [17] .
Since cluster Mm.152484 contains no experimental fulllength cDNA, we constructed an oligo(dT)-primed cDNA library from mouse striatum and screened it with the probe used for Northern hybridization. We obtained two cDNAs that differ in the presence or absence of a 102-bp-long sequence, which is consistent with the Northern results. We deposited the corresponding sequences in GenBank under Accession Nos. AY993933 (long variant) and AY993934 (short variant). Both of them contain the same open reading frame, which starts with an ATG codon in an adequate context [19] and encodes a protein of 237 amino acid residues.
Although containing the full predicted coding sequence, these cDNAs are almost 1 kb shorter than expected from the Northern data. Minute analysis of the striatum SAGE libraries identified a tag (tag 2) matching sequences located 3V of AY993933 and AY993934, but still clustering in Mm.152484. We thus assume that capucin transcripts encompass the cDNAs that we cloned and more 3V ESTs, yielding molecules of the expected size (Fig. 1) . The underrepresentation of distal 3V sequences is probably due to oligo(dT) primer hybridization to a 27-base-long A stretch located between SAGE tags 1 and 2.
The capucin gene spans 21.6 kb on mouse chromosome 12 (12D1). Seventy percent of its length is accounted for by the first intron. The gene comprises five exons, of which the first two are not translated. The difference between AY993933 and AY993934 is explained by the alternative skipping of exon 2 ( Fig. 1) . A gene model (Gm261, predicted cDNA sequence XM _ 138094) has been associated with cluster Mm.152484. It predicts an additional 207-bp-long coding exon between exons 3 and 4. However, the actual existence of this putative exon is not supported by our findings nor any mouse transcribed sequence deposited in GenBank.
We screened the mouse striatum cDNA library for another striatum-enriched transcript originally detected by SAGE and designated as StM6 for striatal marker 6 [17] . We found and deposited a cDNA sequence encoding a protein of 580-amino-acid residues (GenBank Accession No. AY993932). This protein is the mouse ortholog of a recently characterized rat sequence, referred to as protein phosphatase 1 and actin interactor Phactr1 [20] .
Detailed analysis of capucin expression pattern
In a first approach, we used real-time quantitative RT-PCR to assess the expression of capucin in a total of 13 territories sampled from the forebrain (cortical areas, hippocampus, striatum, and thalamus), midbrain (substantia nigra and ventral tegmental area), and hind brain (cerebellum) of wild-type mice. The striatum was divided into a dorsal (caudate -putamen) and a ventromedial part (nucleus accumbens). The whole brain was also included in the analysis to detect any possible prominent expression in an unsampled region (Fig. 2) . Capucin expression was maximal in the caudate -putamen. It was more than 20 times lower in all other regions investigated, except the nucleus accumbens, where it was only 2.3 times lower, and the ventral tegmental area, where it was 6 times lower. Significant expression in the nucleus accumbens is not surprising, since it belongs to the striatal complex and shares many architectural features with the caudate -putamen. Compared to the whole brain, a 13.5-fold enrichment was observed in the caudateputamen, which is consistent with their relative size. Altogether, these results suggest a very restricted expression pattern of capucin in mouse brain.
To refine the analysis of capucin mRNA distribution in mouse fore-and midbrain, we turned to in situ hybridization. Labeling was conspicuous in the striatum (Fig. 3A) , with a marked dorsolateral to ventromedial decreasing gradient (Fig. 3B ). In particular, the signal was much fainter in the nucleus accumbens and olfactory tubercles than in the caudate -putamen. Hybridization to other brain sections revealed the expression of capucin in the shell of the olfactory glomeruli ( Fig. 3C ) and in three diencephalic nuclei: the anterodorsal nucleus of the thalamus, which was intensely stained; the paraventricular nucleus of the thalamus; and the medial habenular nucleus (Fig. 3D) . No signal was visible in the ventral tegmental area. Capucin expression is therefore detectable in only a few discrete regions of mouse brain and is prominent in the dorsolateral part of the striatum. 
Search for capucin homologs
To identify human and rat orthologs of the mouse capucin gene, we aligned mouse capucin cDNAs with all human and rat transcribed sequences deposited in GenBank. In human, we could reconstruct a partial coding sequence from UniGene cluster Hs.12400 and EST DN831347. The corresponding partial protein (TMEM90A, 176 amino acid residues) is 89% identical to mouse capucin (Fig. 4A) . In rat, all the available transcribed sequences matching capucin are located in the 3V-UTR of the gene.
We then searched the UniProt database for proteins sharing sequence homologies with mouse capucin. The transmembrane protein 90B (TMEM90B), a human protein of unknown function, shows a high degree of conservation (59%) with capucin (Fig. 4A) . All other homologies are concentrated within the last 90 carboxy-terminal residues of the proteins (Fig. 4B ). This region relates capucin to two Pfam families: Pfam-B _ 16429, in which the best capucin homologs are clustered (TMEM90B, TMEM91, and PRRT1, all uncharacterized), and the CD225 family, named after a human interferon-inducible leukocyte antigen (interferoninduced transmembrane protein 1), to which more distant homologs belong (PRRT2 and TUSC5, synonym of LOST1, a tumor suppressor candidate in lung cancer [21] ). The conserved region contains two putative transmembrane domains (Fig. 4B) . No other motif was predicted for capucin.
Subcellular localization of EYFP -mouse capucin fusion proteins in two mammalian cell lines
To address the subcellular localization of capucin, we transiently expressed the mouse protein fused to the enhanced yellow fluorescent protein (EYFP) in CHO and HeLa cells. In both cell lines, and irrespective of whether capucin was fused to the amino-or carboxy-terminus of EYFP, we observed a compact juxtanuclear fluorescence in transfected cells (Figs. 5A , 5B, and 5D), reminiscent of the Golgi apparatus. The same results were obtained when EYFP was replaced by the Myc epitope, and the fusion protein was detected by anti-Myc immunofluorescence (data not shown). To validate the possible Golgi localization of the fusion proteins, we treated transfected HeLa cells with brefeldin A (BFA), a fungal metabolite that induces the redistribution of cis and medial Golgi proteins into the endoplasmic reticulum (ER) [22] . Upon BFA treatment, a diffuse reticular pattern of fluorescence characteristic of the ER was consistently observed (Fig. 5C) .
In a second series of experiments, we cotransfected HeLa cells with mouse capucin and human unc-50 homolog (alternatively designated as GMH1), a cis-Golgi membrane protein [23] . Confocal fluorescence microscopic analysis of anti-HA immunofluorescently labeled cotransfected cells revealed colocalization of both proteins (Figs. 5D -5F ), thus demonstrating that EYFP -mouse capucin fusion proteins indeed localize to the cis-Golgi.
Capucin expression in two rodent models of Huntington disease
The genetic basis of Huntington disease consists in an abnormal expansion of a CAG repeat in the first exon of the gene encoding the huntingtin protein [24] . Since huntingtin is ubiquitous, the regional selectivity of the neurodegenerative phenotype might be accounted for by striatum-specific targets or downstream effectors. To investigate the possible involvement of capucin in the pathogenesis of Huntington disease, we measured its expression levels in the striata of 6-week-old wild-type and R6/2 transgenic mice using realtime quantitative RT-PCR. R6/2 mice express a fragment of the diseased human huntingtin-encoding gene, containing about 145 CAG repeats, and develop a progressive neurological phenotype beginning at 2 months of age [25] . Capucin mRNA levels are significantly lower in the striata of R6/2 mice compared to wild-type controls (Fig. 6A) , by an even greater magnitude than Purkinje cell protein 4 and hippocalcin, two transcripts previously demonstrated to be down-regulated in the striata of R6/2 mice [8] .
We also tested capucin expression in a cellular model of Huntington disease, in which primary cultures of rat striatal neurons are infected with a lentiviral vector encoding the amino-terminal part of human huntingtin containing either 19 (control) or 82 (mutant) glutamines. The mutant construct has been shown to induce a progressive pathology specifically affecting striatal neurons [26] . We used real-time RT-PCR to quantify capucin mRNA levels in 8-week-old cultures of striatal neurons infected with either the control or the mutant construct and found a significantly lower expression of capucin in the mutant-infected cultures (Fig. 6B) . Purkinje cell protein 4 was also down-regulated, but interestingly, no change was observed for hippocalcin. Altogether, our results indicate a possible role for capucin in the pathogenesis of Huntington disease.
Discussion
For the purpose of identifying new constitutive markers of mammalian brain regions, we applied the SAGE method to mouse microdissected brain territories. This approach proved successful, as we were able to detect a number of new or poorly documented transcripts showing a heterogeneous distribution in mouse brain [17] . Among these, capucin exhibits a strikingly restricted pattern of expression. Its mRNAs, detectable only in brain and, to a lesser extent, in testis [17] , are essentially confined to the striatum, making it one of the most specific known markers for this structure, comparable, for instance, to protein phosphatase 1 regulatory subunit 1B (usually designated as dopamine-and cAMP-regulated phosphoprotein DARPP-32) [27] , regulator of G-protein signaling 9 (RGS9) [28] , or D1 dopamine receptor [29] . SAGE further provides quantitative information on the expression level of each transcript species detected. Capucin messengers account for about 0.03% of mouse striatum mRNAs, a level in the same range as that of RGS9 or D2 dopamine receptor [17] .
The present in situ hybridization data show decreasing amounts of capucin transcripts from dorsolateral to ventromedial regions of the striatal complex. Gradual differences in connectivity and organization along this axis are abundantly documented. Dorsolateral parts of the striatum receive afferents from the sensorimotor cortex, while inputs to the ventromedial striatum arise from the prefrontal cortex, hippocampus, and amygdala [7] . This segregation pattern is partly paralleled by the distribution of neurochemical markers [2] . In addition to the striatum, which is densely innervated by dopaminergic fibers originating in the midbrain, capucin mRNAs were detected in the shell of olfactory glomeruli, the anterodorsal and paraventricular nuclei of the thalamus, and the medial habenula. Interestingly, all these regions have been reported to receive dopaminergic inputs or express proteins participating in dopaminergic transmission. In the olfactory bulb, a large proportion of periglomerular interneurons synthesize dopamine [30] . Accordingly, high levels of D2 dopamine receptor mRNAs and binding sites have been observed in the glomerular layer [31] . The anterodorsal nucleus is part of the so-called limbic thalamus, which relays information from the hippocampal formation to the retrosplenial cortex. D1 dopamine receptor mRNAs have been detected in this nucleus [29] . As a midline thalamic nucleus, the paraventricular nucleus receives a complex set of afferents and projects to the striatum and prefrontal cortex. Dopaminergic inputs from the midbrain have been demonstrated in both this nucleus and the habenula [32] . The latter structure links the limbic forebrain to midbrain nuclei. It has been involved in a series of biological and behavioral functions. Remarkably, significant expression of DARPP-32 has been reported in the medial habenula [27] .
As it does not depend on the availability of sequence information, the SAGE method is a powerful approach to the discovery of novel transcripts. Before the present study, no experimental cDNA corresponding to capucin had been deposited in public databases. Capucin is closely related to a putative human protein, TMEM90B. Its amino-terminal twothirds does not contain any known functional domains, but remote homologies with the family of interferon-induced transmembrane proteins (IFITMs) can be detected in its carboxy-terminus. IFITM1 (Leu-13) is the best characterized member in this family. On the cell surface of B and L lymphocytes, it is associated with other membrane proteins to form a multimeric complex, which, upon antibody binding, inhibits cell proliferation and promotes homotypic cell adhesion through a tyrosine kinase-dependent pathway [33] .
Heterologous expression of EYFP -mouse capucin fusion proteins in mammalian cell lines indicated a cis-Golgi localization. Proteome analysis of Golgi fractions has indeed revealed that many Golgi proteins remain to be identified [34] . In addition to its crucial role in membrane trafficking and posttranslational modifications, the Golgi apparatus has been implicated in signal transduction. As an illustration, a signaling pathway involving a Golgi-associated Ras protein has recently been discovered [35] .
The high regional specificity of capucin expression suggests an important role in striatal function and pathophysiology. To test this hypothesis, we quantified capucin mRNA levels in two models of Huntington disease: the widely studied R6/2 transgenic mice [25] and a recently developed model resting on infected primary neuronal cultures [26] . In both cases, we observed a highly significant down-regulation of capucin expression. Strikingly, a number of transcripts reported to be down-regulated in R6/2 mice [36, 37] are actually striatal markers (e.g., DARPP-32, preproenkephalin 1, ST8 a-Nacetyl-neuraminide a-2,8-sialyltransferase 3, adenylate cyclase 5, D2 dopamine receptor) [17] . Since expression data are collected before any degenerating neurons can be detected [38] , this observation suggests that striatal function might be specifically targeted in early Huntington disease through the impairment of a regulatory mechanism common to several striatum-enriched species.
Materials and methods
Tissue sampling
For cDNA library construction and tissue distribution analysis of capucin mRNAs, 9-to 10-week-old male C57BL/6 mice (Charles River Laboratories, Les Oncins, France) were deeply anesthetized by intraperitoneal injection of sodium pentobarbital (180 Ag per gram of body weight). After decapitation, the brains were immediately removed, and all subsequent steps were carried out on ice. The motor, cingulate, and somatosensory cortices; hippocampus; caudateputamen; nucleus accumbens; and thalamus were scalpel-dissected from 1-mmthick fresh brain slices cut in a coronal matrix (Pelco International, Redding, CA, USA). The orbital, prelimbic, and entorhinal cortices and the substantia nigra were scalpel-dissected from 0.3-mm-thick fresh brain coronal slices cut using a refrigerated Oxford Vibratome (Vibratome, St Louis, MO, USA). The ventral tegmental area was sampled from 0.3-mm-thick coronal slices using a 0.53-mm diameter punch (Stoelting, Wood Dale, IL, USA). All dissections were performed under stereomicroscopic observation with reference to a mouse brain atlas [39] . Samples from the same brain region were pooled and Douncehomogenized in the appropriate lysis buffer.
To study the regulation of capucin mRNA expression, two rodent models of Huntington disease were studied. The mouse model consisted of 6-week-old R6/2 animals and their corresponding controls [8] . Striata were processed for total RNA extraction as described [8] . The rat model consisted of primary cell cultures generated from E16 ganglionic eminences. The cells were infected with lentiviral constructs 24 h after plating, and total RNAs were extracted 8 weeks later as described [26] .
cDNA cloning
Five micrograms of poly(A) + RNAs isolated from mouse caudate -putamen with Dynabeads mRNA Direct kit (Dynal Biotech, Oslo, Norway) was used for the construction of a ZAP Express library enriched with high-molecular-weight cDNAs (Stratagene, La Jolla, CA, USA). One hundred thousand particleforming units of the amplified library were screened with a capucin-specific oligonucleotide probe ( Fig. 1 ; probe sequence 5V-CAGAGTCAGAAAGAG-CAAGAGATGGCTGGGGC-3V). Hybridizations were carried out at 50-C in Rapid-Hyb buffer (Amersham Biosciences, Little Chalfont, UK) containing 100 Ag/ml poly(A) and 250 fmol/ml (approximately 5 Â 10 6 cpm/ml) probe 3V-end-labeled with [a-32 P]dATP using terminal deoxynucleotidyl transferase. Four positive clones were obtained and excised into pBK-CMV phagemid. One insert corresponded to the capucin long transcript variant, two to the capucin short transcript variant, and one was chimeric.
Sequence alignments
The 5V and 3V ends of mouse capucin transcripts were determined by assembling the cDNA sequences AY993933 and AY993934 with UniGene cluster Mm.152484 ESTs. The resulting sequences were aligned with the mouse genome to describe the structure of the mouse capucin gene and with GenBank human and rat nonredundant and EST sequences to find orthologs of mouse capucin. All nucleic sequence alignments were performed using the BLAST algorithm [40] .
The UniProt curated protein database was searched for capucin homologs using BLAST. Protein sequence alignments were generated by the CLUSTAL W program [41] . Transmembrane domains were predicted using the TMHMM method [42] .
Real-time quantitative RT-PCR
A 107-or 158-bp fragment was amplified from mouse or rat capucin, respectively. PCR was carried out in a 25-Al reaction volume containing Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen, Carlsbad, CA, USA), 10 AM each forward (mouse, 5V-GCAGGAGCATCCAGGAAGGA-GAAAG-3V; rat, 5V-CCCACCTCCACAGACCCT-3V) and reverse (mouse, 5V-GTGGGGCAGCTGCTCACAATGT-3V; rat, 5V-CCGATACCAAGCCTCCAC-3V) primers, and 0.5% random-primed cDNA generated from 200 ng of total RNA. An ABI Prism 7000 thermal cycler (Applied Biosystems, Foster City, CA, USA) was programmed for an initial denaturation step (95-C, 2 min) followed by 40 amplification cycles (95-C for 15 s, 60-C for 1 min). Expression differences were calculated using the amplification rate of the target as evaluated from serial dilutions of whole-brain cDNA and corrected for differences in cDNA input by reference to the expression level of peptidylpropyl isomerase A, assumed to be constant throughout the brain.
The tissue distribution analysis was carried out on two replicates of each sample. For Huntington disease models, triplicate samples were analyzed. The mouse model consisted of four R6/2 mice and four wild-type controls; the rat model of three independent mutant-infected and three control-infected cell cultures. Differences between control and experimental samples were calculated using the 2
ÀDDCt method [43] . Significance was assessed using unpaired Student_s t test.
In situ hybridization T7 (antisense probe) or T3 (sense probe) in vitro transcription was carried out in the presence of 0.5 mM rATP, rCTP, and rGTP; 0.325 mM rUTP; 0.175 mM digoxigenin-11 -UTP (Roche Diagnostics, Mannheim, Germany); and approximately 200 ng of a 1135-bp-long fragment amplified from the mouse capucin coding sequence and 3V-UTR using T3-linked forward (5V-ATTAACCCTCACTAAAGGGAGATCGGTCAAAGAGCCCAAAGC-3V) and T7-linked reverse (5V-TAATACGACTCACTATAGGGGATCAACC-TGCCCTCATTACAGAGC-3V) primers.
After removal, brains were immediately snap-frozen in isopentane at À45-C and stored at À80-C. Twenty-micrometer-thick sections were cut in a CM3050S cryostat (Leica Microsystems, Wetzlar, Germany) and mounted on SuperFrost Plus slides (Menzel-Gläser, Brunswick, Germany). After thawing, sections were fixed in 4% paraformaldehyde for 20 min, rinsed in PBS, and then overlaid with the hybridization solution (195 mM NaCl, 10 mM Tris -HCl, pH 7.5, 5.8 mM Na 2 HPO 4 , 4.2 mM NaH 2 PO 4 , 5 mM EDTA, 50% formamide, 10% dextran sulfate, 1 mg/ml yeast tRNA, 1Â Denhardt_s), containing one-tenth of the in vitro transcription reaction per 100 Al of solution. Following overnight incubation at 68-C, sections were washed at 65-C for 90 min in two changes of a solution of 1Â SSC, 50% formamide, and 0.1% Tween 20. Immunodetection was performed overnight at 4-C in TBS supplemented with 0.1% Tween 20, 0.5% gelatin, and 20% normal goat serum, using a 1:1000 dilution of alkaline phosphataseconjugated Fab fragments (Roche Diagnostics). After extensive washing, slides were transferred into a dark vat filled with a mixture prepared by adding 18 Al of NBT/BCIP stock solution (Roche Diagnostics) per milliliter of a solution of 100 mM NaCl, 100 mM Tris -HCl, pH 9.5, 50 mM MgCl 2 , 0.1% Tween 20, and 500 Ag/ml levamisole. Incubation was continued at room temperature until staining developed. Sections were then counterstained with nuclear fast red (DAKO, Glostrup, Denmark). Negative controls were provided by hybridizing with the sense probe or omitting Fab fragments.
Heterologous expression experiments
Mouse capucin coding sequence was subcloned in frame with EYFP into pEYFP-C1 and pEYFP-N1 CMV-driven mammalian expression vectors (BD Biosciences, Mountain View, CA, USA). An 11-amino-acid-long spacer was inserted between the carboxy-terminus of EYFP and the amino-terminus of capucin, and a 6-amino-acid-long spacer was added between the carboxyterminus of capucin and the amino-terminus of EYFP. HeLa cells were grown in Dulbecco_s modified Eagle medium (DMEM) supplemented with 4.5 g/L dglucose, 25 mM Hepes, l-glutamine, and 10% decomplemented fetal calf serum. CHO cells were grown in DMEM/Ham_s F12 (1:1) medium supplemented with 15 mM Hepes, l-glutamine, pyridoxine -HCl, and 10% decomplemented fetal calf serum. All culture media were purchased from Invitrogen. Transfections were performed with 300 ng of column-purified plasmid and 0.5 Al of Lipofectamine 2000 reagent (Invitrogen) per square centimeter, and heterologous expression was allowed to proceed overnight. If required, cells were subsequently incubated with 5 Ag/ml BFA for 4 h. For colocalization experiments, cells were cotransfected with a plasmid encoding HA-tagged human unc-50 homolog (pEM2) [23] . The HA-tagged protein was detected using a 1:1000 dilution of HA.11 (Covance Research Products, Berkeley, CA, USA) as primary antibody and a 1:100 dilution of Alexa Fluor 594 goat anti-mouse IgG (Invitrogen) as secondary antibody. All observations were made with a confocal Axiovert 200 M microscope (Carl Zeiss, Gö ttingen, Germany).
Acknowledgments
We thank Nicole Déglon (Commissariat à l_Energie Atomique) for giving us access to Huntington disease models, François Leteurtre (Commissariat à l_Energie Atomique) for cell culture facilities and helpful advice, and Anne Peyroche (Commissariat à l_Energie Atomique) for kindly providing plasmid pEM2 and suggesting BFA and colocalization experiments. In situ hybridization images were acquired at the Service Hospitalier JoliotCurie, Commissariat à l_Energie Atomique, Orsay, France.
